PRESS RELEASE published on 10/30/2025 at 07:30, 11 months 18 days ago Informations privilégiées / Autres communiqués GenSight Biologics a obtenu les autorisations réglementaires pour un traitement compassionnel aux États-Unis avec GS010/LUMEVOQ, visant la Neuropathie Optique Héréditaire de Leber FDA GenSight Biologics Neuropathie Optique Héréditaire De Leber GS010/LUMEVOQ Traitement Compassionnel
BRIEF published on 09/29/2025 at 23:05, 1 year ago GenSight Biologics annonce ses résultats financiers du premier semestre 2025 Résultats Financiers Recherche Et Développement Trésorerie GenSight Biologics Programmes D'accès Précoce
BRIEF published on 09/29/2025 at 23:05, 1 year ago GenSight Biologics Announces First Half 2025 Financial Results Financial Results Research And Development Treasury GenSight Biologics Early Access Programs
PRESS RELEASE published on 09/29/2025 at 23:00, 1 year ago Inside Information / News release on accounts, results GenSight Biologics reports 8.3% reduction in operating cash outflow and extends cash runway to late Q4 2025. Company's financial results show decrease in operating income, R&D expenses, and net cash flows Financial Results Operating Income Cash Management GenSight Biologics R&D Expenses
PRESS RELEASE published on 09/29/2025 at 23:00, 1 year ago Informations privilégiées / Communiqué sur comptes, résultats GenSight Biologics publie résultats financiers du premier semestre 2025 : gestion optimisée de trésorerie, financement post-clôture, transfert de fabrication, protocole d'étude soumis à l'ANSM Résultats Financiers Financement Trésorerie GenSight Biologics Étude ANSM
BRIEF published on 08/28/2025 at 20:05, 1 year 1 month ago GenSight Biologics reporte la publication de ses résultats financiers semestriels 2025 Résultats Financiers Conformité Réglementaire Report GenSight Biologics Procédures D'audit
BRIEF published on 08/28/2025 at 20:05, 1 year 1 month ago GenSight Biologics Delays 2025 Half-Year Financial Results Announcement Financial Results Regulatory Compliance Postponement GenSight Biologics Audit Procedures
PRESS RELEASE published on 08/28/2025 at 20:00, 1 year 1 month ago Informations privilégiées / Autres communiqués GenSight Biologics reporte la publication de ses résultats financiers semestriels 2025. Le report est dû à l'audit en cours, non lié à des problèmes financiers. Réunions importantes reprogrammées Résultats Financiers Communication Financière Audit Report GenSight Biologics
PRESS RELEASE published on 08/28/2025 at 20:00, 1 year 1 month ago Inside Information / Other news releases GenSight Biologics postpones the release of its 2025 half-year financial results to September 29, 2025, after the market closes, to ensure highest audit standards. No material issues reported. Audit Committee and Board meetings rescheduled Financial Results Transparency Postponement GenSight Biologics Audit Procedures
Published on 10/17/2026 at 03:20, 18 hours 32 minutes ago Battery X Metals Highlights Participation at X Takeover 2026, an Electric Vehicle and Emerging Technology Event Held at Tesla's Gigafactory Texas, Providing Exposure to Industry Perspectives and Technology Developments
Published on 10/17/2026 at 03:15, 18 hours 37 minutes ago Vanta Closes Second Tranche of Private Placement Financing and Welcomes Launch of First U.S.-Listed Peptide ETF, Highlighting Growing Recognition of Peptide Industry
Published on 10/16/2026 at 23:35, 22 hours 17 minutes ago Initial Closing of US$3.4 Million Private Placement
Published on 10/16/2026 at 23:30, 22 hours 22 minutes ago NiobiumX Mining Inc. Announces Retraction of Recent Marketing Materials
Published on 10/16/2026 at 23:00, 22 hours 52 minutes ago Grid Announces Adoption of Advance Notice By-Law and Provides Shareholder Meeting Update
Published on 10/17/2026 at 18:00, 3 hours 52 minutes ago Baader Bank announces extended trading hours 23 hours a day starting Q1/2027
Published on 10/17/2026 at 13:05, 8 hours 47 minutes ago Luong Quoi Coconut Vietnam to Showcase Vietnamese Coconut Expertise at SIAL Paris 2026
Published on 10/17/2026 at 12:50, 9 hours 2 minutes ago AGFUND wins international award for excellence in inclusive banking and social impact
Published on 10/16/2026 at 20:08, 1 day 1 hour ago EQS-Adhoc: Rath AG // Rath Group reaches agreement with its key financial creditors on the terms of a transformation agreement and launches a transformation programme
Published on 10/16/2026 at 19:20, 1 day 2 hours ago Arity to Acquire INRIX, Advancing a Connected Vision for the Future of Transportation
Published on 10/16/2026 at 19:54, 1 day 1 hour ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 30 septembre 2026
Published on 10/16/2026 at 18:48, 1 day 3 hours ago Disclosure of transactions in own shares from October 12 to October 16, 2026
Published on 10/16/2026 at 18:48, 1 day 3 hours ago Déclaration hebdomadaire d'opérations effectuées du 12 au 16 octobre 2026
Published on 10/16/2026 at 18:00, 1 day 3 hours ago KLARSEN : Compte rendu AGO et AGE du 8 octobre 2026
